Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00150449

Enrollment

511

Registered

2005-09-08

Start date

2001-01-31

Completion date

2006-03-31

Last updated

2006-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Neuroses

Brief summary

Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.

Interventions

DRUGPregabalin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must have completed the double-blind portion of the preceding trial * Completed any protocol specified withdrawal phase and follow-up visits.

Exclusion criteria

* Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.

Design outcomes

Primary

Measure	Time frame
Safety Tolerability	—

Countries

Austria, Belgium, Estonia, France, Germany, Israel, Italy, Latvia, Netherlands, Poland, South Africa, Spain, Ukraine, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026